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It remains unknown how autoimmunity is elicited,
although many different mechanisms have been
involved. There is a major difficulty in establishing a
correlation between triggering events and the actual
autoimmune disease because of long prodromal period.
In this regard, previous studies reported that sera
obtained from the acute stage of SJS/TEN and erythema
multiforme contain autoantibodies (autoAbs) against
epidermal proteins. Unfortunately, however, it remains
to be determined whether generation of these autoAbs
could be a mere epiphenomenon of epidermal damage
or if there could be a link between SJS/TEN and the
subsequent risk of developing autoAbs and autoimmune
blistering disease. Thus, there is a great need for longi-
tudinal analyses are generated by using samples
obtained at various time points including those during
the acute stage of the disease and long after their clini-
cal resolution.We retrospectively analyzed sera serially
collected from 27 DiHS, 9 TEN, 30 SJS and 7 healthy
controls for the presence of autoAbs against epidermal
proteins such as plakins and recombinant periplakinN1-
324. These autoAbs were detected in 23.3% (SJS), 55.6%
(TEN) and 48.1% (DiHS) of patients, respectively. These
autoAbs tended to disappear much earlier in SJS/TEN
than in DiHS. Because the existence of these autoAbs
was not restricted to patients with SJS/TEN but was
extended to those with DiHS characterized by no
epidermal damage. These results clearly indicate that
those autoAbs are not the cause of epidermal damage.
According to our previous study, the time-dependent
defective regulatory T cell (Treg) responses occur during
the acute stage (SJS/TEN) and after clinical resolution
(DiHS), respectively. The defects of Treg function could
provide explanation of why autoimmune responses can
be generated during the acute stage(SJS/TEN)and after
resolution (DiHS), respectively. Surprisingly, our analysis
of the effect of systemic corticosteroids during the acute
stage of DiHS on the generation of those autoAbs showed
that achievement of early resolution by corticosteroids was
associated with a lower risk of subsequently generating
autoAbs. In conclusion, self-inflicted immune responses
occurring during the acute stage of severe drug eruptions
could be a trigger for the subsequent development of
AutoAbs. Longitudinal analyses of these autoAbs offer the
possibility for screening high-risk patients at a time before
the development of overt autoimmune disease.
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